论文部分内容阅读
该研究旨在评估比较单独用辛伐他汀治疗、强化他汀类药物治疗、联合辛伐他汀和依折麦布治疗的首发心肌梗死患者的全因死亡率。尽管使用了他汀类药物,心肌梗死患者残余心血管风险仍存在。治疗方案包括药效更强的他汀类药物或加用依折麦布,目前尚无在此类患者中使用依折麦布的临床预后资料。方法:从英国全科研究数据库获取资料,进行回顾性纵向研究。纳入首发急性心肌梗死(first acute myocardial infarct,AMI)后存活30d,先前未接受他汀类药物或依折麦布治疗,且在AMI发生后30d内开始他汀类
The study was designed to evaluate all-cause mortality in patients with first-episode myocardial infarction compared with simvastatin alone, intensive statin therapy, simvastatin and ezetimibe. Despite statin use, residual cardiovascular risk remains in patients with myocardial infarction. Treatment options include more potent statins or the addition of ezetimibe, and no ezetimibe clinical data are available for such patients. METHODS: Data were obtained from the UK GPR database for a retrospective longitudinal study. After the first acute myocardial infarction (AMI) was enrolled, it survived for 30 days and had not been previously treated with statins or ezetimibe, and statins started within 30 days after AMI